Cellular Health Screening Test Market Size and Trends
The global cellular health screening test Market size is expected to reach US$ 6.61 billion by 2030, from US$ 2.90 billion in 2023, at a CAGR of 12.5% during the forecast period.
Global Cellular Health Screening Test Market Trends:
- Increasing Investments in Cellular Ageing Research: Cellular ageing and biomarkers related to longevity are a key research focus in the healthcare industry. Several companies and research institutes are actively investigating associations between biochemical biomarkers like telomere length, epigenetic changes, senescent cell accumulation, and human healthspan. An aging population also underscores the need for advancing cellular ageing science. The insights from this emerging research are expected to bolster the adoption of cellular tests that assess biological age.
- Development of Integrated Multi-analyte Assays: Diagnostics companies are developing integrated assays that combine markers of oxidative stress, inflammation, hormones, vitamins, and cellular aging. Multi-analyte panels provide a more comprehensive snapshot of overall cellular health compared to individual biomarker tests. For example, In May 2022, C₂N Diagnostics, a leader in advanced brain health diagnostics that offers the PrecivityAD blood test as an aid to Alzheimer's disease diagnosis, announced its latest innovative offering for enhancing care in brain health: a high-resolution mass spectrometry-based plasma tau multi-analyte assay (p-tau MAA) for Research Use Only (RUO). This assay uses a small sample of blood to precisely and simultaneously measure different phosphorylated and nonphosphorylated forms of the tau protein including forms with phosphorylation at the tau217 and tau181 sites
- Partnerships between Diagnostics and Pharmaceutical Companies: Collaborations between diagnostics developers and pharmaceutical companies are on the rise to co-develop companion diagnostic tests for drugs under clinical evaluation. Cellular screening tests can potentially serve as companion diagnostics to identify patient subgroups most likely to benefit from certain therapies. For instance, an oxidative stress biomarker test can aid in testing drugs that target cellular oxidative damage pathways. These strategic partnerships will support the utility of cellular screening.
- Growing Industry Focus on Liquid Biopsy Testing: Liquid biopsy tests that analyze biomarkers in blood, urine, or saliva are gaining significant market focus driven by their non-invasive nature. Cellular screening tests perfectly align with the liquid biopsy theme by measuring multiple biochemical markers from such samples. Leading diagnostics companies are actively expanding their liquid biopsy product portfolios. The liquid biopsy trend will further propel research and funding for cellular biomarker assays.
U.S.: 
U.K. : 
India : 
